Clinical Trial Results

Stockholm – October 05, 2026 -- Moberg Pharma AB (OMX: MOB) reported that its topical onychomycosis treatment MOB-015 achieved mycological cure in 74.3% of evaluable Phase 3 patients regardless of baseline antifungal susceptibility, according to new peer-reviewed data published in the Journal of Fungi.

Researchers screened 506 dermatophyte isolates for terbinafine resistance markers

The analyses draw on the company's completed North American Phase 3 trial of MOB-015, a once-daily treatment applied for 48 weeks. The work was conducted with Professor Mahmoud Ghannoum at Case Western Reserve University in Cleveland, Ohio, examining in vitro terbinafine susceptibility across the full isolate population.

Hiroshima – October 3, 2026 -- Ractigen Therapeutics presented first-in-human data showing its systemically delivered small activating RNA (saRNA), RAG-18, produced 3.5- to 5.3-fold increases in sarcolemmal utrophin expression in boys with Duchenne muscular dystrophy (DMD), marking the first clinical proof-of-mechanism for RNA activation (RNAa) in a monogenic disease. The data were disclosed in a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle Society (WMS 2026) in Hiroshima, Japan.

Milan – October 02, 2026 -- Hansoh Pharma's dual-biased GLP-1/GIP receptor agonist Olatorepatide (HS-20094) achieved a mean weight loss of 19.3% at Week 48 in the 15 mg dose group of a Phase III Chinese trial, with no plateau observed in the weight-loss curve.

The data, presented as a Late-breaking Abstract oral presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting running September 28 to October 2, 2026 in Milan, come from the LIGHTEN study, a multicenter, randomized, double-blind, placebo-controlled trial enrolling 604 Chinese adults with overweight or obesity.

Trial enrolled 604 participants across four dose arms over 48 weeks

Participants with a BMI of 28 kg/m2 or above, or 24-28 kg/m2 with a weight-related comorbidity, were randomized 1:1:1:1 to once-weekly subcutaneous Olatorepatide at 5mg, 10mg or 15mg, or placebo. A total of 90.1% completed the full 48-week treatment period.

Paramus, N.J. – October 01, 2026 -- NS Pharma, Inc. reported 5-year efficacy and safety data showing its investigational therapy brogidirsen maintained or improved motor function in Duchenne muscular dystrophy (DMD) patients amenable to exon 44 skipping, with zero treatment discontinuations across the study period.

Six-participant trial records no serious adverse events over five years

The data, presented by Japan's National Center of Neurology and Psychiatry (NCNP) at the 31st annual International Congress of the World Muscle Society in Hiroshima, Japan, covered an open-label extension of an investigator-initiated clinical trial. All six participants received weekly intravenous dosing of brogidirsen (NS-089/NCNP-02), an antisense oligonucleotide co-discovered by Nippon Shinyaku and NCNP. After five years of administration, no serious or severe adverse events, anaphylaxis, or discontinuations tied to long-term dosing were recorded.

Indianapolis – – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) reported that its oral GLP-1 therapy Foundayo (orforglipron) reduced cardiovascular death risk by 53% and all-cause death risk by 57% compared with insulin glargine in the Phase 3 ACHIEVE-4 trial, the largest and longest study of the medicine in type 2 diabetes to date.

Foundayo meets non-inferiority bar on major cardiovascular events

Among 2,749 participants randomized across 16 countries including the U.S., Germany, India, Brazil and South Korea, Foundayo showed a 16% lower risk of MACE-4 (cardiovascular death, heart attack, stroke or hospitalization for unstable angina) versus insulin glargine, with a hazard ratio of 0.84 (95.0% CI: 0.59 to 1.20), meeting the prespecified non-inferiority threshold. The risk of MACE-3 (cardiovascular death, heart attack or stroke) was 23% lower (hazard ratio: 0.77; 95.0% CI: 0.52 to 1.13).

Indianapolis – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) reported that its investigational triple hormone receptor agonist retatrutide produced an average weight loss of 49.6 lbs (20.8%) over 80 weeks at the 12 mg dose in patients with type 2 diabetes and obesity, with more than half of participants no longer meeting BMI criteria for obesity. The Phase 3 TRIUMPH-2 results were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan and simultaneously published in The Lancet.

Highest dose delivers weight loss up to 23.4% in heavier patients

Across the three tested doses, participants lost an average of 29.8 lbs (12.7%) at 4 mg, 45.4 lbs (19.1%) at 9 mg, and 49.6 lbs (20.8%) at 12 mg. Among patients with a baseline BMI of 35 or higher, the 12 mg dose produced an average loss of 60.8 lbs (23.4%), with 59.5% of all 12 mg participants no longer classified as having obesity by trial end.

Indianapolis – September 29, 2026 -- Eli Lilly and Company said a new indirect treatment comparison shows Zepbound (tirzepatide) 15 mg produced 4.5% greater body-weight loss than Novo Nordisk's Wegovy HD (semaglutide 7.2 mg) in adults with obesity, intensifying the competitive battle in the obesity-drug market. The 10 mg dose of Zepbound delivered 3.2% greater weight reduction than Wegovy HD, according to data presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan.

Indianapolis – September 29, 2026 -- Eli Lilly and Company (NYSE: LLY) reported that its oral GLP-1 drug Foundayo (orforglipron) at 17.2 mg produced 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg over 52 weeks in adults with type 2 diabetes, based on an indirect treatment comparison presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan.

Indirect analysis draws on ACHIEVE-3 and PIONEER PLUS trial data

The comparison, covariate-adjusted for gender, age, baseline A1C and baseline weight, found weight-loss differences ranging from 1.5% to 2.4% and A1C reductions of 0.3% to 0.6% in favor of Foundayo 17.2 mg across multiple statistical methods. The 95% confidence interval for weight loss was -2.7% to -0.2%, and for A1C reduction was -0.6% to -0.1%.

Hong Kong – – September 28, 2026 -- Ascletis Pharma Inc. (HKEX: 1672) reported a 48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI) scores from a 28-day U.S. proof-of-concept trial of ASC50, an oral small molecule IL-17A inhibitor positioned as a needle-free alternative to injectable antibody therapies for plaque psoriasis.

Once-daily 200 mg dosing matched published efficacy benchmarks for injectable IL-17A antibody secukinumab

The randomized, double-blind, placebo-controlled Phase I study (NCT07024602) enrolled mild-to-moderate plaque psoriasis patients who received once-daily 200 mg oral ASC50 for 28 days. Ascletis said the PASI reduction was comparable to published secukinumab data, though the comparison was not conducted head-to-head.

Shanghai – September 26, 2026 -- IASO Biotechnology's CAR-T therapy FUCASO achieved a 95.9% objective response rate and 77.2% complete/stringent complete response rate in a real-world study of 281 heavily pretreated Chinese patients with relapsed or refractory plasma cell neoplasms, data presented at the 2026 International Myeloma Society Annual Meeting show.

Real-world cohort skews higher-risk than pivotal trial population

The multicenter study tracked patients treated since FUCASO's June 2023 launch across China. Median age was 61 years, with 18.7% aged 70 or older, and patients had received a median of four prior therapy lines, up to 12. Prior anti-CD38 exposure reached 84.0%, 27.4% were penta-exposed, and 46.9% had undergone autologous stem cell transplantation. High-risk cytogenetic abnormalities affected 82.4% of patients, 50.5% were ISS stage III, 7.8% had plasma cell leukemia, and 47.0% presented extramedullary disease.